Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 14/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621105 | 0.99 | TBXA2R (0.34) | TBXA2RTBXAS1PSEN1PSEN2APH1B | |
| SCHEMBL7628012 | 0.95 | TBXAS1 (0.36) | TBXA2RTBXAS1MAPTHPGDMAPK1 | |
| SCHEMBL7624569 | 0.94 | TBXAS1 (0.36) | TBXA2RTBXAS1MAPTPSEN1PSEN2 | |
| SCHEMBL7624607 | 0.92 | PSEN1 (0.39) | TBXA2RTBXAS1PSEN1PSEN2APH1B | |
| SCHEMBL7618235 | 0.92 | MAPT (0.34) | MAPTHPGDMAPK1L3MBTL1 | |
| SCHEMBL7618139 | 0.91 | POLB (0.34) | TBXA2RTBXAS1MAPTHPGD | |
| SCHEMBL7621844 | 0.91 | PSEN1 (0.39) | TBXA2RTBXAS1PSEN1PSEN2APH1B | |
| SCHEMBL7624587 | 0.91 | MAPT (0.32) | TBXA2RTBXAS1MAPTHPGDMAPK1 | |
| SCHEMBL7622724 | 0.90 | POLB (0.34) | TBXA2RTBXAS1MAPTHPGD | |
| SCHEMBL7617025 | 0.90 | MAPT (0.31) | MAPTHPGDMAPK1L3MBTL1PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | TBXA2R 2665/4885TBXAS1 1565/4885MAPT 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.